Search Results
142 results found-
If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration.
https://newsroom.csl.com/2025-02-07-CSL-Behrings-Gene-Therapy-HEMGENIX-R-etranacogene-dezaparvovec-drlb-Four-Years-Post-Infusion-Data-Continue-to-Show-Sustained-Efficacy-and-Safety-in-Adults-with-Hemophilia-B -
If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration.
https://newsroom.csl.com/2023-06-20-CSL-Behring-Announces-the-First-Patient-Has-Received-FDA-Approved-HEMGENIX-R-etranacogene-dezaparvovec-drlb-for-Hemophilia-B -
5 Modelling suggests the true burden of flu may be even higher than reported.
https://newsroom.csl.com/2025-04-02-Influenza-cases-already-at-highest-to-date-with-vaccines-now-available -
Iron deficiency affects one in every two hospitalized patients with heart failure 5 .
https://newsroom.csl.com/2024-03-19-Ferinject-R-approved-by-Health-Canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure -
In PROTECT, the most common adverse reactions (≥ 5%) were peripheral edema, hypotension (including orthostatic hypotension), dizziness, hyperkalemia, and anemia.
https://newsroom.csl.com/2024-04-24-CSL-Vifor-and-Travere-Therapeutics-Announce-European-Commission-approves-FILSPARI-R-sparsentan-for-the-treatment-of-IgA-Nephropathy -
The most common side effects (incidence ≥5%) were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea and feeling unwell.
https://newsroom.csl.com/2022-11-22-U-S-Food-and-Drug-Administration-approves-CSLs-HEMGENIX-R-etranacogene-dezaparvovec-drlb-,-the-first-gene-therapy-for-hemophilia-B